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Purpose: An independent Safety Review Committee (SRC), supported by Novartis Pharma AG, analyzed
investigator-reported cases of intraocular inflammation (IOI), endophthalmitis, and retinal arterial occlusion in the
phase 3 HAWK and HARRIER trials of brolucizumab versus aflibercept in neovascular age-related macular
degeneration (nAMD).
Design: A post hoc analysis of a subset of data from two 2-year, double-masked, multicenter, active-
controlled randomized phase 3 trials (NCT02307682, NCT02434328).
Participants: Patients (N ¼ 1817) with untreated, active choroidal neovascularization due to age-related
macular degeneration in the study eye were randomized and treated in HAWK/HARRIER. The SRC reviewed
data from cases of investigator-reported IOI (60/1088 brolucizumab-treated eyes; 8/729 aflibercept-treated eyes).
Methods: The SRC received details and images (color fundus photography, fluorescein angiography, and
OCT) for all investigator-determined cases of IOI, retinal arterial occlusion, and endophthalmitis. Cases were
reviewed in detail by 2 readers, then adjudicated by the SRC as a group.
Main Outcome Measures: Within this patient subset: incidence of IOI, signs and incidence of retinal
vasculitis and/or retinal vascular occlusion, and visual acuity loss; time since first brolucizumab injection to IOI
event onset; and frequency of visual acuity loss after brolucizumab injection by time of first IOI event onset.
Results: Fifty brolucizumab-treated eyes were considered to have definite/probable drug-related events
within the spectrum of IOI, retinal vasculitis, and/or vascular occlusion. On the basis of these cases, incidence of
definite/probable IOI was 4.6% (IOI þ vasculitis, 3.3%; IOI þ vasculitis þ occlusion, 2.1%). There were 8 cases
(incidence 0.74%) of at least moderate visual acuity loss (15 ETDRS letters) in eyes with IOI (7 in eyes with IOI þ
vasculitis þ occlusion). Of the 8 cases, 5 experienced their first IOI-related event within 3 months of the first
brolucizumab injection (increasing to 7/8 within 6 months). Incidence of IOI in aflibercept-treated eyes was 1.1%,
with at least moderate visual acuity loss in 0.14%.
Conclusions: This analysis of IOI cases after brolucizumab injection identified signs of retinal vasculitis with
or without retinal vascular occlusion and an associated risk of visual acuity loss. The findings will help physicians
to evaluate the risks and benefits of brolucizumab treatment for nAMD. Ophthalmology 2020;-:1e10 ª 2020 by
the American Academy of Ophthalmology. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Supplemental material available at www.aaojournal.org.Choroidal neovascularization is the hallmark of neovascular
age-related macular degeneration (nAMD) and a major
cause of vision loss.1,2 Vascular endothelial growth
factor (VEGF) is a key mediator of intraocular
neovascularization, and intravitreal injection of anti-VEGF
agents is the gold standard for treatment of nAMD.3 Anti-
VEGF agents including aflibercept (Eylea; Regeneron),
ranibizumab (Lucentis; Genentech), and bevacizumab
(Avastin; Genentech) have demonstrated efficacy to reduceª 2020 by the American Academy of Ophthalmology
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/). Published by Elsevier Inc.vision loss and improve visual acuity in phase 3 clinical
trials.4 Systematic comparison of data from trials of
aflibercept, ranibizumab, and bevacizumab in nAMD has
revealed little difference between their efficacy and safety
profiles.5,6 These drugs are generally well tolerated. The
systemic safety profile is favorable, and rates of
cardiovascular or cerebrovascular events are typically
low.7-9 One of the main ocular adverse events (AEs) asso-
ciated with these agents is intraocular inflammation (IOI).101https://doi.org/10.1016/j.ophtha.2020.11.011
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nAMD were treated with intravitreal ranibizumab or
aflibercept, IOI was a predefined AE of interest.11
Between baseline and 96 weeks, this event was reported
in 1.5% of patients receiving ranibizumab and 0.5% to
1.1% of patients in the three aflibercept arms.11
Brolucizumab (Beovu, Novartis Pharma AG) is a hu-
manized monoclonal single chain Fv antibody fragment
that binds with high affinity to isoforms of VEGF-A and
prevents binding of VEGF-A to its receptors VEGF
receptor-1 and VEGF receptor-2.12,13 Brolucizumab was
approved for the treatment of nAMD based on data from
the phase 3 HAWK and HARRIER clinical trials, which
demonstrated that best-corrected visual acuity with brolu-
cizumab (dosed every 12 or 8 weeks after a loading phase
with injections at weeks 0, 4, and 8) was noninferior to
aflibercept (dosed every 8 weeks after a loading phase with
injections at weeks 0, 4, and 8).14 These visual gains were
maintained to week 96.15 The incidence of serious ocular
AEs in the study eye to week 96 was low (<4%) in both
trials, and reduced visual acuity was reported as an AE in
similar proportions of brolucizumab-treated (6.1%e9.5%)
and aflibercept-treated (7.0%e8.1%) patients.15
Since the approval of brolucizumab, a number of post-
marketing cases of severe visual acuity loss associated with
retinal vasculitis and retinal artery occlusion (also described
in combination as retinal occlusive vasculitis) have been
reported after treatment.16,17 In February 2020, the
American Society of Retinal Specialists indicated that it
had “received reports of inflammation which included
more than a dozen cases of vasculitis, of which greater
than two-thirds were designated as occlusive retinal
vasculitis by the reporting providers.”18 On August 28,
2020, postmarketing data indicated that Novartis had
received reports of evidence of associated retinal
vasculitis and retinal vascular occlusion at a rate of 4.71
per 10 000 brolucizumab injections, while individual
events of retinal vasculitis and retinal vascular occlusion
were reported at rates of 3.61 and 2.35 per 10 000
injections, respectively.19 Novartis has concluded that
there is a confirmed safety signal of rare AEs of retinal
vasculitis and/or retinal vascular occlusion that may result
in severe visual acuity loss. Typically, these events
occurred in the presence of IOI.19 To evaluate the relative
risks and benefits of brolucizumab with respect to this
new safety signal, there is a need to understand the
incidence of these signs of retinal vasculitis and/or retinal
vascular occlusion.
In patients treated with 6 mg brolucizumab in HAWK
and HARRIER, the incidence of IOI reported by the in-
vestigators was 4%.13 The clinical dataset for these
investigator-reported cases of IOI provided an opportunity
for the Safety Review Committee (SRC) to determine the
incidence of definite/probable signs of retinal vasculitis and
retinal vascular occlusion, as well as any associated loss of
visual acuity, within this subset of patients. We report the
findings of this post hoc analysis.2
Methods
Role of the SRC
The SRC was commissioned by Novartis Pharma AG to provide an
independent, standardized assessment of postmarketing reports of
patients treated with brolucizumab. The SRC then reviewed cases
of IOI, endophthalmitis, and retinal arterial vasculitis in the Phase 3
HAWK and HARRIER trials to determine whether the post-
marketing reports represented a new safety signal.
The SRC comprised global retina and uveitis specialists and
imaging experts (5 from United States, 3 from Europe) and
ophthalmology experts (4 from United States, 2 from Europe) from
two separate external Data Monitoring Committees (responsible for
monitoring ongoing brolucizumab trials in diabetic macular edema/
retinal vein occlusion). An observer from the American Society of
Retinal Specialists also attended meetings. Details of the
SRC members are available in Table S1 (available at
www.aaojournal.org). The SRC had full autonomy with respect
to the analysis and assessment of the cases, conclusions formed,
and content of this manuscript. Quality checks were performed
by Novartis to ensure accuracy.
Source Data
HAWK and HARRIER were two similarly designed 2-year,
double-masked, multicenter, active-controlled, randomized phase 3
clinical trials (NCT02307682, NCT02434328). The studies were
conducted in accordance with principles of the Declaration of
Helsinki, International Conference on Harmonization E6 Good
Clinical Practice Consolidated Guideline, and other regulations as
applicable, and were compliant with the Health Insurance Porta-
bility and Accountability Act of 1996. All patients provided written
informed consent before screening or initiation of any study-related
procedures. Protocols were approved by an Independent Ethics
Committee/Institutional Review Board. Full details of the trial
oversight, randomization, sample size calculations, and inclusion
and exclusion criteria have been published previously.14
Briefly, 1817 eyes of 1817 participants with untreated nAMD
were randomized to intravitreal brolucizumab (3 mg [HAWK only]
or 6 mg; n ¼ 1088) or aflibercept (2 mg; n ¼ 729). Loading
injections were given at weeks 0, 4, and 8 in both groups, and then
brolucizumab injections were administered every 12 weeks
(adjusted to 8 weeks if disease activity was present); aflibercept
was given every 8 weeks. The primary efficacy end point was mean
best-corrected visual acuity change from baseline to week 48. To
assess safety, all AEs, serious AEs, ophthalmic examinations (slit-
lamp biomicroscopy, intraocular pressure measurements, and
fundus examinations), postinjection assessments (including intra-
ocular pressure), clinical laboratory testing (hematology, blood
chemistry, and urinalysis), vital sign measurements, and physical
examination results were collected. Serum samples were also
assessed for systemic brolucizumab levels and antidrug antibodies.
Review Process
The SRC analyzed investigator-reported cases of IOI, endoph-
thalmitis, and retinal arterial occlusion. The SRC determined
whether cases were likely to be drug related and within the
spectrum of IOI, retinal vasculitis, and/or retinal vascular occlu-
sion; each was designated as definite, probable, or not. Definitions
of events and outcomes were proposed a priori and evolved during
the review based on observations made by the SRC. The emphasis
Monés et al  IOI Cases in two Brolucizumab Phase 3 Trialswas on inclusion of the investigator-reported cases within the
spectrum rather than exclusion from the spectrum; in cases where
the findings were equivocal, the SRC always erred on the side of
considering the cases drug related and within the spectrum, unless
evidence overwhelmingly contradicted this decision.
The SRC also reviewed all cases of investigator-reported IOI,
retinal occlusion, and endophthalmitis in the aflibercept cohorts.
Treatment assignment was available for all patients reviewed.
Ophthalmic images obtained at standard study and unscheduled
visits from before any IOI event and throughout the follow-up
visits were reviewed. Images could include color fundus photog-
raphy (CFP), fluorescein angiography (FA), and OCT, although all
images were not available at all visits because this was not required
in the protocol. In general, OCT was available at all visits.
Scheduled CFP was performed at screening, week 12, week 48,
week 96, and at some unscheduled visits if the investigator chose to
obtain them. Images were carefully evaluated to assess retinal
arteriolar and venous caliber, and to determine whether there was
segmental vascular sheathing and/or vessel emboli. Secondary
occlusion manifestations, including cotton wool spots, retinal
hemorrhages, and retinal whitening, also were recorded.
Scheduled FA was also performed at screening, week 12, week
48, week 96, and at some unscheduled visits if the investigator
chose to obtain them; review included identification of any
vascular abnormalities on early and late images. Sequelae of
inflammation including disc hyperfluorescence/leakage and
vascular leakage were also identified. Images were examined for
evidence of vascular occlusion, including nonperfusion, attenua-
tion of arterial and/or venous flow, and choroidal perfusion
changes.
Scheduled OCT was performed monthly at each study visit.
OCT volume scans were reviewed for each time point before and
after the event. OCT scans were evaluated for changes in the vit-
reous, including increased opacity suggestive of vitreous inflam-
mation, vitreous hyper-reflective spots consistent with vitreous
cells, and changes within the retina suggestive of occlusive disease.Outcomes
The incidence of definite/probable cases of IOI, IOI with signs of
retinal vasculitis, and IOI with signs of retinal vasculitis and retinal
vascular occlusion was reported for all eyes treated with brolucizu-
mab in the combined HAWK and HARRIER population, and within
subgroups (retinal vasculitis within subgroup with IOI; retinal
occlusion within subgroup with IOI þ retinal vasculitis). Retinal
vasculitis was identified based on imaging findings such as vascular
sheathing on CFP and staining or leakage from vessels on FA. Signs
of arteriolar occlusion included retinal whitening or emboli on CFP,
inner retinal hyperreflectivity on OCT, and boxcarring or arteriolar
attenuation and nonperfusion on FA.
The incidence of visual acuity loss within these groups was also
reported. Visual acuity was obtained at each visit following a
defined protocol using ETDRS charts. At least moderate visual
acuity loss was defined as loss of at least 15 ETDRS letters, with
severe loss defined as the loss of at least 30 ETDRS letters. Visual
acuity loss was based on last available visual acuity measurement
versus baseline.
The time from first brolucizumab injection to the first onset of
IOI-related event was reported, along with the frequency of visual
acuity loss after brolucizumab injection by time of first onset of
IOI-related event.
The incidence of IOI and visual acuity loss were also reported
for eyes treated with aflibercept in HAWK and HARRIER.Statistical Analysis
No formal statistical hypothesis testing was performed as part of
this post hoc review of clinical trial data.Results
Analysis Population (Brolucizumab-Treated
Eyes)
A total of 1088 eyes of 1088 participants were treated with
brolucizumab in the HAWK and HARRIER trials.14 The SRC
reviewed a total of 60 brolucizumab-treated eyes of 60 participants
with investigator-reported IOI and/or retinal artery occlusion and/or
retinal vasculitis and/or endophthalmitis. Of these 60 cases, 39 had
IOI only, 8 had IOI and retinal artery occlusion, 2 had IOI and
endophthalmitis, 3 had retinal artery occlusion alone, 1 had peri-
vascular sheathing, and 7 had endophthalmitis alone. An additional 3
cases were reviewed from a HAWK extension study but were not
included in the incidence calculations because of differences in study
design.
In the 60 eyes, 28 investigator-reported events were categorized
as “definite,” and 22 investigator-reported events were categorized
as “probable,” with regard to being both drug related and within the
spectrum. The remaining 10 investigator-reported events were
categorized as “not drug related, not in spectrum.” The reasons
eyes were excluded included endophthalmitis (culture-proven or
per investigator; n ¼ 4), presence of inflammation at baseline
(n ¼ 2), retinal artery occlusion without IOI (n ¼ 1), unexplained
inflammation after cataract surgery (n ¼ 1), baseline leakage at disc
(n ¼ 1), and macular hole (n ¼ 1). All data for brolucizumab-
treated eyes presented in this article relate to the 50 eyes with
events categorized as definite or probable.
Incidence of Definite/Probable IOI, Retinal
Vasculitis, and Retinal Vascular Occlusion
Events (Brolucizumab-Treated Eyes)
Of the 50 eyes with definite/probable IOI events, 36 showed signs
of retinal vasculitis. In turn, 23 of these cases showed signs of
retinal vasculitis þ retinal occlusion. The incidence rates of these
events in the total HAWK and HARRIER population, and within
each subgroup are shown in Figure 1. In HAWK and HARRIER,
the incidence of definite/probable IOI was 4.6%, IOI þ retinal
vasculitis was 3.3%, and IOI þ retinal vasculitis þ retinal
occlusion was 2.1%. In eyes with definite/probable IOI (n ¼ 50),
the incidence of retinal vasculitis was 72.0%; in eyes with
IOI þ retinal vasculitis (n ¼ 36), the incidence of retinal
occlusion was 63.9%. Representative images of typical cases are
available in Figure S1 (available at www.aaojournal.org).
Risk of Visual Acuity Loss Associated with IOI
 Retinal Vasculitis  Retinal Vascular Occlusion
Events
There were 8 cases of at least moderate visual acuity loss (15
ETDRS letters), 5 of which were severe (30 ETDRS letters),
among eyes with definite/probable IOI (Table 1). All but 1 of these
cases occurred in eyes with definite/probable IOI þ retinal
vasculitis þ retinal occlusion. The other case (moderate
visual acuity loss) occurred in an eye with definite/probable
IOI þ retinal vasculitis but without retinal occlusion.3
Figure 1. Incidence of intraocular inflammation (IOI), IOI with retinal vasculitis, and IOI with retinal vasculitis and retinal occlusion: definite and probable
cases combined (brolucizumab-treated eyes). Numbers relate to all cases categorized as “definitely drug related; within spectrum of IOI, retinal vasculitis and/
or retinal vascular occlusion” or “probably drug-related; probably in the spectrum.” HAWK and HARRIER incidence based on all 1088 patients analyzed
from HAWK and HARRIER studies. Subgroup incidence based on subgroup with IOI (n ¼ 50) or IOI with retinal vasculitis (n ¼ 36), as appropriate. H/
H ¼ HAWK and HARRIER.
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Vasculitis, and Retinal Vascular Occlusion and
Visual Acuity Loss Events (Brolucizumab-
Treated Eyes)
The median (range) number of days from the last injection to the
onset of event was 25.5 (1e91) for IOI, 22 (1e49) for
IOI þ retinal vasculitis, and 25 (3e49) for IOI þ retinal
vasculitis þ retinal occlusion. The frequency distribution of time
since first injection for definite/probable IOI-related event is shown
in Figure 2, and time to event curves are shown in Figure 3.
Approximately three quarters of cases of each event occurred
within the initial 6 months after the first injection. Approximately
half of cases occurred within the first 3 months (IOI, 24/50
[48.0%]; IOI þ retinal vasculitis, 18/36 [50.0%]; IOI þ retinal
vasculitis þ retinal occlusion, 13/23 [56.5%]). There were 8
cases of definite/probable IOI (5 of these with definite/probable
retinal vasculitis þ retinal occlusion) that occurred in patients
who had received only 1 injection.
The frequency distribution of “at least moderate visual acuity
loss likely due to the inflammation event” by time of first onset of
definite/probable IOI-related event since first injection is shown in
Figure 4A. Among eyes with at least moderate visual acuity loss
likely due to the inflammation event, more than one half of the
first investigator-reported IOI-related events occurred within 3
months of the first injection (IOI, 5/8 [62.5%]; IOI þ retinal
vasculitis, 5/8 [62.5%]; IOI þ retinal vasculitis þ retinal occlusion,
4/7 [57.1%]). A similar pattern was observed for cases of “severe
visual acuity loss likely due to the inflammation event” (IOI, 3/5
[60.0%]; IOI þ retinal vasculitis, 3/5 [60.0%]; IOI þ retinal
vasculitis þ retinal occlusion, 3/5 [60.0%] associated with events
occurring in the first 3 months; Fig 4B).
Analysis of Eyes Treated with Aflibercept
In HAWK and HARRIER, 729 eyes of 729 participants were treated
with aflibercept.14 A total of 8 eyes with IOI were identified by
investigators from the aflibercept groups; the overall incidence4
was 1.1% (8/729). The overall risk of at least moderate visual
acuity loss in eyes with IOI in the aflibercept arms of the HAWK
and HARRIER trials was 0.14% (1/729), with a risk of 12.5% (1/
8) in the affected subpopulation.
Overall Loss of Visual Acuity in the HAWK and
HARRIER Studies
The overall rates of moderate or severe visual acuity loss, including
visual acuity loss associated with definite/probable IOI, retinal
vasculitis, and/or retinal occlusion, were 7.4% (81/1088) and 7.7%
(56/729) in brolucizumab- and aflibercept-treated eyes, respectively.
Discussion
In response to postmarketing reports of severe vision loss,
retinal arterial/vascular occlusion, and vasculitis in patients
treated with brolucizumab, this analysis evaluated rates of
inflammatory events in the investigator-reported cases of
IOI in the phase 3 HAWK and HARRIER clinical trials. In
HAWK and HARRIER, Medical Dictionary for Regulatory
Activities (MedDRA) terms were used to code AEs based
on investigator reports. Codes for retinal vasculitis and
retinal occlusive vasculitis are not included in the MedDRA
terms. Thus, in some cases, the investigator chose IOI terms,
and in others, retinal artery or vein occlusion; this made
discovering retinal occlusive vasculitis difficult.
In the current post hoc analysis, the committee performed
extensive and thorough review of potential cases to provide
clinical case identification and description without regard to
the MedDRA terms. Based on the 60 investigator-reported
cases, among which 50 were classified by the SRC as
definitely/probably within the spectrum of IOI, retinal
vasculitis, and/or retinal vascular occlusion, the incidence of
IOI in brolucizumab-treated eyes in HAWK and HARRIER
Table 1. Cases of Visual Acuity Loss by Intraocular Inflammation, Retinal Vasculitis, and Retinal Occlusion Grouping: Definite and
Probable Cases Combined (Brolucizumab-Treated Eyes)







n/N % n/N %
Visual acuity loss, cases with IOI
At least moderate 8 8/1088 0.74% 8/50 16.0%
Severe 5 5/1088 0.46% 5/50 10.0%
Visual acuity loss, cases with IOI without retinal vasculitis
At least moderate 0 0/1088 0.0% 0/14 0.0%
Severe 0 0/1088 0.0% 0/14 0.0%
Visual acuity loss, cases with IOI þ retinal vasculitis
At least moderate 8 8/1088 0.74% 8/36 22.2%
Severe 5 5/1088 0.46% 5/36 13.9%
Visual acuity loss, cases with IOI þ retinal vasculitis without retinal occlusion
At least moderate 1 1/1088 0.09% 1/13 7.69%
Severe 0 0/1088 0.0% 0/13 0.0%
Visual acuity loss, cases with IOI þ retinal vasculitis þ retinal occlusion
At least moderate 7 7/1088 0.64% 7/23 30.4%
Severe 5 5/1088 0.46% 5/23 21.7%
IOI ¼ intraocular inflammation.
Numbers relate to all cases categorized as “definitely drug related; within spectrum of IOI, retinal vasculitis and/or retinal vascular occlusion” or “probably
drug-related; probably in the spectrum.”
At least moderate visual acuity loss defined as 15 ETDRS letter loss; severe visual acuity loss as 30 ETDRS letter loss.
*HAWK and HARRIER incidence based on rate of visual acuity loss due to the adverse event (AE) in all 1088 patients analyzed in HAWK/HARRIER.
ySubgroup incidence based on rate of visual acuity loss in patients for whom the AE is present.
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treated eyes). The observed incidence of definite/probable
IOI with signs of retinal vasculitis was 3.3% and definite/Figure 2. Frequency distribution of time since first injection (months) by onset
Note that categories are not mutually exclusive. IOI þ retinal vasculitis þ retin
IOI ¼ intraocular inflammation.probable IOI with signs of retinal vasculitis and retinal
vascular occlusion was 2.1% in brolucizumab-treated eyes.
Additional cases may have been identified if the SRC hadcategory: definite and probable cases combined (brolucizumab-treated eyes).
al occlusion is a subset of IOI þ retinal vasculitis, which is a subset of IOI.
5
Figure 3. Time since first injection to first IOI-related event (KaplaneMeier plot; brolucizumab-treated eyes). Note that categories are not mutually
exclusive. IOI þ retinal vasculitis þ retinal occlusion is a subset of IOI þ retinal vasculitis, which is a subset of IOI. AE ¼ adverse event; IOI ¼ intraocular
inflammation.
Ophthalmology Volume -, Number -, Month 2020applied the conservative review to all patients in the two
studies. The purpose of this analysis was to assess these
events in brolucizumab-treated eyes and not to compare
them with aflibercept. Cases of IOI in aflibercept-treated
eyes were not fully analyzed; therefore, it is inappropriate
to draw conclusions between the two treatments in this case.
Uncontrolled postmarketing data, which may be derived
from cases in treatment-naïve patients as well as patients
switched from other anti-VEGF treatments, are subject to
limitations, including inconsistencies in diagnostic criteria,
incomplete documentation, and considerable possibility of
underreporting. The findings of this analysis represent a
valuable resource on which physicians may base decisions
relating to the risks and benefits of brolucizumab in patients
with treatment-naïve nAMD. A direct comparison of the
reported incidence rates with those identified in the post-
marketing setting is not appropriate. However, the findings
of the current analysis, together with the published efficacy
and safety data from HAWK and HARRIER, can be used
by clinicians to make informed decisions regarding the use
of brolucizumab in their patients with nAMD. To help put
the findings into context, the incidence of inflammatory
events in other studies of anti-VEGF agents may be
considered, although it is important to acknowledge dif-
ferences in methodology used to identify cases. In the
CATT trials, endophthalmitis occurred in the study eye of
0.7% of patients treated with monthly ranibizumab (plus an
additional 0.3% with pseudoendophthalmitis) and 1.4% of
patients treated with monthly bevacizumab.20 A wide range
of IOI rates after bevacizumab treatment has been reported6
in single-center studies (0.3% to 14.3%).10 A large
retrospective, claims-based analysis (N ¼ 432 794 in-
jections) reported that severe IOI occurred at a rate of 1.06/
1000 aflibercept injections and 0.64/1000 ranibizumab in-
jections.21 A recent review of data from the postmarketing
aflibercept Global Safety Database indicated that
retinal arterial occlusion, vasculitis, or severe vision
loss occurred at a rate of 0.9 per 10 000 aflibercept
injections.22
Three-quarters of the inflammation events were first
observed within 6 months after initiation of brolucizumab,
although some occurred between 12 and 18 months after the
treatment. It is important for clinicians to be aware that
although the risk of inflammation is highest soon after in-
jections are given, ongoing vigilance is vital because epi-
sodes may still occur more than 1 year postinjection.
Notably, patients whose first IOI-related event occurred
more than 12 months after the first injection had no reported
vision loss at the end of the study.
In this post hoc analysis, the overall incidence of at least
moderate visual acuity loss associated with IOI was <1%
in both brolucizumab- and aflibercept-treated eyes. In
brolucizumab-treated eyes with definite/probable IOI, the
risk of at least moderate visual acuity loss was 22.2% in
eyes with signs of retinal vasculitis and 30.4% in eyes with
signs of retinal vasculitis þ retinal occlusion. In
brolucizumab-treated eyes with definite/probable IOI, the
risk of severe visual acuity loss was 13.9% in eyes with
signs of retinal vasculitis and 21.7% in eyes with signs of
retinal vasculitis þ retinal occlusion. Despite these data,
Figure 4. Frequency distribution of cases of (A) at least moderate or (B) severe visual acuity loss likely due to the inflammation event by time of onset of first
IOI-related event since first injection (brolucizumab-treated eyes). Note that categories are not mutually exclusive. IOI þ retinal vasculitis þ retinal
occlusion is a subset of IOI þ retinal vasculitis, which is a subset of IOI. IOI ¼ intraocular inflammation.
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(including that associated with definite/probable IOI,
retinal vasculitis and/or retinal occlusion) were similar for
brolucizumab and aflibercept (7.4% and 7.7%, respec-
tively). The time course and severity of visual acuity loss
may be sensitive to whether signs of retinal vasculitis and/
or retinal vascular occlusion are present with IOI. It has
been demonstrated that some aflibercept-treated eyes
benefit from a monthly dosing interval.23 Certain eyes from
either treatment group in HAWK and HARRIER might
have experienced better preservation of visual acuity if
their dosing frequency had been increased.
The SRC adopted a thorough, discussion-based approach
to review the cases that ensured generalizability of these
findings to clinical practice. The study population was suf-
ficiently large to support analysis of the incidence of un-
common events. Although the source population was
defined by the enrolment criteria of HAWK and HARRIER,
analysis of cases was performed using clinically relevant
methodology. However, the analysis was subject to a
number of limitations. As described, the SRC applied a
cautious approach to the analysis and included both definite
and probable cases of IOI/retinal vasculitis/retinal vascular
occlusion in their calculations of incidence. The inclusion of
“questionable” cases must be taken into consideration when
interpreting the incidence rates presented. The SRC’s
retrospective review depended on the imaging available for
analysis. Color fundus photography was only obtained at
limited intervals and typically included 30-degree field
posterior pole images, which limited the assessment of the
peripheral retina. Likewise, fluorescein angiograms were
usually not widefield and limited in number, preventing the
assessment of peripheral vasculitis signs and retinal blood
flow. The SRC only reviewed cases in which IOI,
endophthalmitis, and retinal arterial occlusion had been re-
ported by investigators; these cases tended to have more
imaging available around the time of the event. The actual
event rate may have been higher than reported by the in-
vestigators, particularly if some of the cases were minimally
symptomatic or asymptomatic. This analysis was limited to
treatment-naïve patients as per HAWK and HARRIER
inclusion criteria; no conclusions can be drawn relating to
the incidence of these AEs in patients with a history of anti-
VEGF therapy. Finally, the findings and their description
will have been affected by the premature study8
discontinuation of some patients, and it is important to
recognize that no formal statistical comparisons were per-
formed for this post hoc analysis.
Based on the findings of this analysis, we encourage vig-
ilance in practice, with active surveillance and prompt
reporting of cases of IOI, retinal vasculitis, and retinal oc-
clusion. Routine monitoring should be more comprehensive
than that typically performed in clinical practice, incorpo-
rating slit-lamp examination and ophthalmoscopy combined
with fundus imaging (if inflammation is suspected). Careful
examination of fundus imaging in some cases revealed subtle
vasculitis and/or occlusive disease that could not be appre-
ciated on dilated fundus examination. OCT scans should be
reviewed for signs of inflammation. A full description of the
analysis of images by the SRC will be published in due
course. Brolucizumab is contraindicated in patients with
active IOI.12,13 If inflammation is detected, injections should
cease, widefield FA or FA with peripheral sweeps should be
performed, and systemic and/or local corticosteroid treatment
considered. Analysis suggested there may be an association
between inflammatory events and boosted or emergent
antidrug antibodies; this observation is under further
evaluation by Novartis.
In conclusion, this rigorous analysis of cases of definite/
probable IOI that occurred in the phase 3 HAWK and
HARRIER clinical trials identified a number of cases with
signs of retinal vasculitis with or without signs of retinal
vascular occlusion, and such events were associated with
increased risk of visual acuity loss. It is critical that treating
physicians monitor appropriately for this safety signal dur-
ing brolucizumab treatment. These findings will help phy-
sicians to make informed decisions when balancing these
risks against the demonstrated efficacy and durability of
brolucizumab in nAMD.
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